52nd week of 2010 patent applcation highlights part 44 |
Patent application number | Title | Published |
20100330069 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE - Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided. | 2010-12-30 |
20100330070 | Methods Of Making An Antibody And Compositions Thereof - The present invention relates to new methods for making antibodies that involves chemically modifying the antigen with methylglyoxal. The present invention further relates to antibodies made in this manner, and include antibodies specific to LL-37. The present invention pertains to assays that utilize anti-LL-37 antibodies and assess compounds that stimulate LL-37 production. Such compounds are useful in antimicrobial compositions. | 2010-12-30 |
20100330071 | METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE - The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described. | 2010-12-30 |
20100330072 | Myostatin binding agents - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 2010-12-30 |
20100330073 | METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA - The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders. | 2010-12-30 |
20100330074 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 2010-12-30 |
20100330075 | MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY - Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described. | 2010-12-30 |
20100330076 | IMMUNOGLOBULIN FC POLYPEPTIDES - Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fe domain that selectively binds FcγRI at a level within 2-fold of a glycosylated Fc domain, but that is significantly reduced for binding to other Fc receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain. | 2010-12-30 |
20100330077 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY - Compounds of general formula (I) | 2010-12-30 |
20100330078 | ALPHA 5 - BETA 1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 2010-12-30 |
20100330079 | BIOMARKDER COMBINATIONS FOR COLORECTAL CANCER - The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal cancer. | 2010-12-30 |
20100330080 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 2010-12-30 |
20100330081 | CRIPTO BINDING MOLECULES - The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof and their use in treating disorders, such as cancer either alone or in combination with other agents. | 2010-12-30 |
20100330082 | NLRR-1 ANTAGONISTS AND USES THEREOF - NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided. | 2010-12-30 |
20100330083 | PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS - A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution. | 2010-12-30 |
20100330084 | SINGLE DOMAIN VHH ANTIBODIES AGAINST VON WILLEBRAND FACTOR - The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 2010-12-30 |
20100330085 | METHOD OF TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF PATHOLOGIES OF THE BONE - The present invention relates generally to the fields of treatment, prophylaxis and diagnosis. More particularly, the present invention identifies genes and gene products associated with bone morphogenesis and pathologies of the bone. Even more particularly, the present invention contemplates the regulation of expression of these genes or the activity of the gene products in the treatment, prophylaxis and diagnosis of bone pathologies. Cell-based therapies and manipulation of cells in in vitro culture also form part of the present invention. | 2010-12-30 |
20100330086 | CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA). | 2010-12-30 |
20100330087 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY - The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof. | 2010-12-30 |
20100330088 | STRATEGIES TO PREVENT AND/OR TREAT IMMUNIE RESPONSES TO SOLUBLE ALLOFACTORS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a soluble allofactor and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore. | 2010-12-30 |
20100330089 | ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS - The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases. | 2010-12-30 |
20100330090 | ANTAGONIST ANTIBODIES OF PROTEASE ACTIVATED RECEPTOR-1 (PAR1) - The present invention provide antibodies or antigen-binding molecules that specifically recognize and antagonize the PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors. | 2010-12-30 |
20100330091 | IMMUNOREACTIVE GLYCOPROTEIN GP19 EHRLICHIA CANIS - The present invention concerns gp19 immunoreactive compositions for | 2010-12-30 |
20100330092 | MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13 - A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention. | 2010-12-30 |
20100330093 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4). | 2010-12-30 |
20100330094 | Anti-IP-10 Antibodies and Methods of Use Thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder. | 2010-12-30 |
20100330095 | AXL ANTIBODIES - The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity. | 2010-12-30 |
20100330096 | METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES - The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample. | 2010-12-30 |
20100330097 | PREDICTING AMD WITH SNPS WITHIN OR NEAR C2, FACTOR B, PLEKHA1, HTRA1, PRELP, OR LOC387715 - Gene polymorphisms and genetic profiles associated with an elevated or a reduced risk of a complement cascade dysregulation disease such as AMD are disclosed. Methods and reagents for determination of risk, diagnosis and treatment of such diseases are provided, as well as methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases are provided. | 2010-12-30 |
20100330098 | METHODS TO REGULATE GLUCOSE METABOLISM - The present disclosure describes an unexpected and novel insight into hepatic insulin resistance through the description of the ability of VEGF inhibitors to revert hyperglycemia and hyperinsulimenia in murine Type 2 diabetes mellitus models through modulation of a HIF-2α-IRS-2 axis operative in hepatocytes. As such, the data of the present disclosure uncover a novel pathway regulating hepatic IRS-2 expression, and identify VEGF inhibitors as an FDA-approved class of therapeutics capable of increasing liver IRS levels and ameliorating Type 2 diabetes mellitus. Accordingly, this disclosure identifies stabilization of HIF-2α as a robust method for improving glucose metabolism. The disclosure provides embodiments of a method of modulating the level of glucose metabolism of a mammalian cell, comprising: contacting a mammalian cell with an effective amount of a composition, where the composition can modulate the levels of HIF-2α and IRS-2 activity in said cell, thereby modulating the level of glucose metabolism by said cell. The disclosure also provides embodiments of a pharmaceutical composition and methods for their use for the treatment of Type 2 diabetes in an animal or human subject, the method comprising administering to an animal or human subject a effective amount of a pharmaceutically acceptable composition, the composition, when administered to an animal or human subject, increasing the activity of HIF-2α and IRS-2 in the animal or human subject, thereby reducing the level of blood glucose in the animal or human subject. | 2010-12-30 |
20100330099 | STABILIZED ANTI-HEPATITIS B (HBV) ANTIBODY FORMULATIONS - The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention. | 2010-12-30 |
20100330100 | PSEUDOMONAS AERUGINOSA-OUTER MEMBRANE PROTEIN PA4710 - An object is to provide: a protein antigen or a peptide antigen usable as a vaccine composition which has an ability to practically prevent or treat a | 2010-12-30 |
20100330101 | BIFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION - A bifunctional composition comprising an intracellularly effective immunomodulating nucleic acid component containing at least one immunostimulatory, immunoinhibitory or immunomodulating motif and selected from a mononucleotide, a dinucleotide, an oligonucleotide or a polynucleotide with either a natural phosphodiester backbone or a modified backbone, optionally in combination with a specific antigen, in association with a protein binding to specific receptors on mammalian cell surfaces selected from the group consisting of cholera toxin (CT), the subunit B of CT (CTB), | 2010-12-30 |
20100330102 | IMMUNOGLOBULIN PREPARATION FOR THE TREATMENT OF HIV-1 INFECTION - An immunoglobulin (Ig) preparation containing polyclonal IgG-reactive antibodies (Abs), methods for preparing said preparation and pharmaceutical compositions containing it in admixture with suitable excipients, the use of said preparation or composition, alone or in combination with antiretroviral drugs, for the prophylaxis or treatment of HIV-1 infection. | 2010-12-30 |
20100330103 | Antibodies Directed to Alpha V Beta 6 And Uses Thereof - Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed. | 2010-12-30 |
20100330104 | METHODS OF USING BTL-II PROTEINS - The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen. | 2010-12-30 |
20100330105 | Anticancer Combination Therapies - Methods for treating or preventing hyperproliferating diseases, e.g., cancer, are described. A method may comprise administering to a subject in need thereof a therapeutically effective amount of a chemotherapeutic agent and a DNA vaccine. | 2010-12-30 |
20100330106 | Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of DII4 antagonists, in particular, DII4 antibodies and fragments thereof that specifically bind human DII4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing DII4 antagonists and chemotherapeutic agents are also provided. | 2010-12-30 |
20100330107 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 2010-12-30 |
20100330108 | PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE - The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases. | 2010-12-30 |
20100330109 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 2010-12-30 |
20100330110 | THERAPEUTIC AND DIAGNOSTIC USES OF ANTIBODY SPECIFICITY PROFILES - This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection. | 2010-12-30 |
20100330111 | INCREASE OF IMMUNE RESPONSE AND TARGETING BY ANTIGENS AND/OR DRUG LINKAGE - The present invention relates to compounds consisting of glycolipids covalently bound to an antigen or a drug via a linker. The said compounds are able to induce a stronger immune response than a composition comprising separated glycolipids and antigen. The said compounds are also able to target drug to CD1d restricted cells. | 2010-12-30 |
20100330112 | VACCINES AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE - Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically. | 2010-12-30 |
20100330113 | Vaccine Antigens - The present invention discloses novel proteins, e.g., antigens. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from | 2010-12-30 |
20100330114 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response - The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4 | 2010-12-30 |
20100330115 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 2010-12-30 |
20100330116 | LIVE ATTENUATED SALMONELLA FOR USE AS VACCINE - The present invention relates to live attenuated | 2010-12-30 |
20100330117 | PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, NON-VIRAL BASED CANCERS, ALZHEIMERS'S DISEASE, MUSCULAR DYSTROPHY, ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, COMPLEX REGIONAL PAIN SYNDROME, DIABETES, NEUROPATHIC PAIN, SPIDER ARTHRITIS, WEST NILE VIRUS, FIBROMYALGIA, SHINGLES, GOUT, MIGRAINE HEADACHES, SENILE DEMENTIA, POST POLIO SYNDROME, CENTRAL VIRUS DEAFNESS, ASTHMA, CHRONIC PAIN OF UNKNOWN ORIGIN AND HEPATITIS C - The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, Alzheimer's disease, ALS, Guillain-Barre syndrome, atherosclerosis, schizophrenia, Tremors/Parkinsons's disease, senile dementia, Muscular Dystrophy, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Complex Regional Pain Syndrome, Diabetes, Neuropathic Pain, Spider Arthritis West Nile Virus, Fibromyalgia, Shingles, Gout, Migraine Headaches, Post Polio Syndrome, Central Virus Deafness, Asthma, Chronic Pain Of Unknown Origin and Hepatitis C and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostate cancer and others realized immediate beneficial results with no side effects. | 2010-12-30 |
20100330118 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided. | 2010-12-30 |
20100330119 | CHROMATOGRAPHY MEDIUM, PREPARATION METHOD OF THE SAME, AND METHOD FOR PRODUCING VIRUS VACCINE USING THE CHROMATOGRAPHY MEDIUM - A Chromatography medium having the properties of high virus adsorption and high fluidity, and a method for producing a virus vaccine using these are provided. The Chromatography medium is formed by binding a sulfated polysaccharide to porous particles having an exclusion limit molecular weight of 6000 Da or less when pure water is used as mobile phase and standard polyethylene glycol is used and an average particle size in the range of 30-200 μm. | 2010-12-30 |
20100330120 | HUMAN PARAINFLUENZA VIRUSES HAVING SEPARATED P AND C GENES - The invention provides self replicating infectious recombinant paramyxoviruses where the P and C genes are separated rated. The recombinant paramyxoviruses preferably have one or more attenuating mutations and/or at least one temperature sensitive mutation and one non-temperature sensitive mutation. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a C protein and a separate monocistronic polynucleotide encoding a P protein. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein. | 2010-12-30 |
20100330121 | RECOMBINANT ALPHAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACRO-MOLECULAR SYNTHESIS - Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules. | 2010-12-30 |
20100330122 | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS - The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects. | 2010-12-30 |
20100330123 | ALBUMIN-FREE BOTULINUM TOXIN FORMULATIONS - This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations. | 2010-12-30 |
20100330124 | VACCINE COMPOSITIONS AND METHODS OF USE TO PROTECT AGAINST INFECTIOUS DISEASE - The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus | 2010-12-30 |
20100330125 | NOVEL POLYSACCHARIDE IMMUNOGENS FROM CLOSTRIDIUM DIFFICILE - The application relates to | 2010-12-30 |
20100330126 | Attenuated malaria blood-stage vaccine - The present invention relates to an attenuated | 2010-12-30 |
20100330127 | SOLUBLE AGGREGATE, IMMUNE TOLERANCE INDUCER AND MANUFACTURING METHOD THEREOF - A soluble aggregate of allergen proteins, prepared by heating multiple allergen proteins and aggregating the allergen proteins and thus enclosing the antigen structures causing allergic reactions therein. | 2010-12-30 |
20100330128 | Method of improving immune function in mammals using lactobacillus strains with certain lipids - A method of improving immune-function in mammals using selected 3-HPA producing lactic acid bacteria with a medium chain triglyceride (MCT) oil. | 2010-12-30 |
20100330129 | Gastroresistant Pharmaceutical Formulations Containing Rifaximin - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 2010-12-30 |
20100330130 | SUBSTANTIALLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N-(4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1-carbonyl)-piperazin-1-ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure α-form of imatinib mesylate. | 2010-12-30 |
20100330131 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2010-12-30 |
20100330132 | COMPOSITE PARTICLES, METHOD FOR PREPARING THE SAME AND COSMETIC COMPOSITION - Composite particles formed of core particles and a silicone elastomer adhered to surfaces of the core particles. | 2010-12-30 |
20100330133 | METHOD AND COMPOSITION FOR IMPROVING SKIN COMPLEXION - Extracts of at least one, and preferably a mixture of, encapsulated mixed plant carbohydrates (polysaccharides) are applied topically to the skin to mitigate the appearance of wrinkled skin and to improve the overall complexion of the skin. The mixed plant extracts are preferentially applied in a dehydrated state, with a preferred source for the polysaccharides being cacti. The application vehicle is preferentially an anhydrous product, which allows slight penetration of smaller fractions of the dehydrated mixed cactus carbohydrate into the stratum corneum. Upon entering the stratum corneum the cactus carbohydrates begin to hydrate and swell resulting in a plumping effect, with the overall appearance of lines and wrinkles diminishing. | 2010-12-30 |
20100330134 | Depilatory Composition - A depilatory composition comprising glucose syrup and a viscosity modifier comprising dextrose powder and/or crystals. | 2010-12-30 |
20100330135 | COSMETIC COMPOSITION - A cosmetic composition contains: a carotenoid (A), a collagen (B) having an average molecular weight of 40,000 or more, and a collagen peptide (C) having a weight average molecular weight of from 200 to 5,000. | 2010-12-30 |
20100330136 | USE OF CATIONIC SURFACTANTS FOR THE PROTECTION AGANST TOOTH EROSION - This invention relates to a use of a composition for protecting oral cavity and teeth containing ethyl-Nα-lauroyl-L-arginate HCl (LAE), a corresponding composition and a corresponding method for protecting teeth. Because of nearly epidemic incidence of dental erosion, there is a continuing need for improved products that provide protection against dental erosion. Hence, it is an object of the present invention to protect teeth against dental erosion. Surprisingly, it has been found that ethyl-N | 2010-12-30 |
20100330137 | HIGH BIOAVAILABILITY FORMULATION OF MANGOSTEEN AND MANUFACTURING PROCESS THEREOF - The present invention relates to a pharmaceutical or dietary composition containing Mangosteen (Garcinia Mangostana pericarp) and being characterized by high bioavailability. A process for the manufacture of this composition is a further object of the present invention. In particular, the present invention relates to a composition containing Mangosteen extract and oligosaccharides in an amount ranging from 5 to 50 w/w % with respect to the Mangosteen extract or a fermented Mangosteen product and to a process for obtaining thereof. | 2010-12-30 |
20100330138 | BIOSTABLE, MULTIPURPOSE, MICROBICIDAL INTRAVAGINAL DEVICES - Biostable, multipurpose, microbicidal intravaginal devices in the form of rings, ringed-meshes, sponges, or diaphragms for use by women and condoms for use by male partners are provided, wherein each of the devices contains a drug effective in treating a particular vaginal infection, while further exhibiting at least one additional function selected from the group dealing with non-hormonal contraception, management of sexually transmitted diseases, viral infections, and retroviral infections as well as the treatment of cervical cancer. | 2010-12-30 |
20100330139 | Substrate With Low Residue Cleaning Composition - The present invention relates to substrate loaded with a cleaning composition containing C8-C10 alkylpolyglucosides which have low filming and streaking when combined with C2-C4 alcohols. The cleaning composition may also comprises a C2 to C4 alcohol, a water-soluble organic acid and a glycerol. The cleaning composition may optionally comprise dyes, builders, fatty acids, fragrances, colorants, glycerol, anti-foaming agents, and preservatives. The nonwoven substrate material comprises unmodified and modified natural fibers. The nonwoven substrate material is at least 90% biodegradable under compost conditions. The substrate loaded with the cleaning composition is also at least 90% biodegradable under compost conditions. | 2010-12-30 |
20100330140 | DEVICES AND METHODS FOR DECREASING HUMAN PATHOGEN TRANSMISSION - A facial mask for use in decreasing the transmission of one or more than one human pathogen to and from a human wearer of the facial mask, the facial mask comprising a facepiece; where the facepiece comprises three or more than three layers; where one or more than one of the three or more than three layers comprises a fabric comprising one or more than one binding substance comprising one or more than one human pathogen binding group for chemically attaching the human pathogen to the binding substance; where the fabric further comprises one or more than one type of multivalent metallic ion or metallic salt; and where one or more than one of the three or more than three layers comprises a heat-moldable fabric. | 2010-12-30 |
20100330141 | PRODUCT FOR ABSORPTION PURPOSES - A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl carbamoyl chloride (DACC) and the positively charged entity comprises polyethyleneimine (PEI). The product is capable of removing microorganisms, including viruses, from air and liquid. Methods for manufacturing the product and uses and applications of the product are also presented. | 2010-12-30 |
20100330142 | Antimicrobial Compositions - The invention relates to a composition comprising a) silver and/or one or more silver compound and b) one or more biocidal active ingredients of the isothiazoline. | 2010-12-30 |
20100330143 | MODIFIED MACROMOLECULES AND METHODS OF MAKING AND USING THEREOF - Described herein are composites produced by reacting a first thiolated macromolecule with at least one compound having at least one thiol-reactive electrophilic functional group. The methods described herein permit the cross-linking of a variety of different thiolated macromolecules with one another. The composites described herein have a variety of biomedical and pharmaceutical applications, which are also described herein. | 2010-12-30 |
20100330144 | Methods and Apparatus for Fabricating Porous Three-Dimensional Tubular Scaffolds - Disclosed herein are three-dimensional porous tubular scaffolds for cardiovascular, periphery vascular, nerve conduit, intestines, bile conduct, urinary tract, and bone repair/reconstruction applications, and methods and apparatus for making the same. | 2010-12-30 |
20100330145 | BIOBENEFICIAL COATING COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided. | 2010-12-30 |
20100330146 | CONTACT LENSES FOR EXTENDED RELEASE OF BIOACTIVE AGENTS CONTAINING DIFFUSION ATTENUATORS - An appliance for the delivery of at least one bioactive agent to the eye has at least one diffusion attenuator within a hydrophilic or silicone-hydrogel contact lens. The bioactive agent can be a drug or a nutraceutical. The diffusion attenuator can be a plurality of solid particles or phase separated liquid aggregates within at least one continuous phase of the lens where the diffusion attenuators promote a tortuous path for the diffusion of the bioactive agent to mediate the rate by which the bioactive agent diffuses from the contact lens. The diffusion attenuator can be homogeneously dispersed throughout at least one continuous phase of the lens to modify the diffusivity of the bioactive agent through that phase. The diffusion attenuator can have little or no affinity for the bioactive agent or can be miscible with the bioactive agent. The diffusion attenuator can be incorporated while forming the contact lens by polymerization of a monomer mixture containing the diffusion attenuator. For liquid diffusion attenuators, the liquid can be co-absorbed with a solvent into the lens followed by removal of the solvent, where the bioactive agent can be co-absorbed or subsequently absorbed after the loading of the diffusion attenuator. The diffusion attenuator can be Vitamin E. | 2010-12-30 |
20100330147 | Drug Delivery Compositions Including Nanoshells For Triggered Drug Release - The current invention is directed to compositions comprising a plurality of particles including nanoshells or a medical device with a coating including nanoshells allowing for triggered drug release. Methods of treatment with such compositions are also included. | 2010-12-30 |
20100330148 | MEHODS AND COMPOSITIONS FOR INHIBITING IMPDH-1 ISOFORM 1 - Described herein are methods of inhibiting IMPDH type 1, and treating or preventing a disease or disorder (or symptoms thereof) associated with IMPDH type 1, wherein an IMPDH type 1 inhibitor compound is administered to a subject. | 2010-12-30 |
20100330149 | Solid Drug Tablets for Implantable Drug Delivery Devices - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 2010-12-30 |
20100330150 | Orally Disintegrating Tablet Compositions Comprising Combinations of High and Low-Dose Drugs - The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked high-dose/low-dose drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of high-dose and low-dose drugs which provide for more convenient and palatable administration of drug combinations, for example for treating pain, hyperglycemia, cardiovascular disease, and allergies. | 2010-12-30 |
20100330151 | Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate - The present invention is directed to a method of treating or maintaining protection from episodic gastrointestinal disturbances, by providing a composition comprising a probiotic microorganism and chocolate wherein said probiotic microorganism is selected from the group consisting of | 2010-12-30 |
20100330152 | METHODS AND COMPOSITONS FOR ANTISENSE VEGF OLIGONUCLEOTIDES - This invention relates to compositions and methods for inhibition of abnormal proliferation of cells or angiogenesis. More particularly this invention provides VEGF antisense oligonucleotides capable of inhibiting proliferation of cancer cells or angiogenesis or combinations thereof. also provided are screening and prognostic assays, as well kits comprising the VEGF antisense oligonucleotides. | 2010-12-30 |
20100330153 | METHOD FOR PRODUCING BIOLOGICALLY INGESTIBLE MATERIAL AND BIOLOGICALLY INGESTIBLE MATERIAL OBTAINED THEREFROM - The present invention provides a production method for obtaining a biologically ingestible material having an intended diameter with low energy as compared with conventional methods, the method includes mixing a fluid to be processed in a dispersed phase containing a pharmacologically active substance and a fluid to be processed in a continuous phase including at least a disperse solvent, while each of the fluids are retained in an independent state, in a thin film fluid formed between two processing surfaces arranged to be opposite to each other to be able to approach to and separate from each other, at least one of which rotates relative to the other, through independent pathways corresponding to the respective phases, whereby the components contained in the fluid to be processed in a dispersed phase are formed into microparticles having a desired diameter. | 2010-12-30 |
20100330154 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS - An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients. | 2010-12-30 |
20100330155 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA - The present invention relates to chemically modified, linked double-stranded (ds)RNA compositions comprising two or more double-stranded (ds) oligoribonucleotides linked by at least one linking moiety and methods of formulating and delivering such compositions to modulate gene expression through target-specific RNA co-interference (RNAco-i). The compositions of the invention may optionally comprise a conjugation or a complex with one or more small molecule drugs, protein therapeutics, or other dsRNA molecules. The present invention is directed at the methods of production for, methods of use of, and therapeutic utilities for RNAi co-interference therapy utilizing the compositions of the invention. | 2010-12-30 |
20100330156 | PHENAZINE DERIVATIVES AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2010-12-30 |
20100330157 | BIOMATERIAL FOR THE CONTROLLED DELIVERY OF INGREDIENTS - The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial. The disclosure can particularly be used in the field of cosmetics and pharmaceuticals. | 2010-12-30 |
20100330158 | PROTEIN-ASSISTED DRUG DELIVERY SYSTEM FOR THE TARGETED ADMINISTRATION OF ACTIVE AGENTS - The present invention provides a composition and prodrug for targeted drug delivery to the central nervous system of a patient. The inventive composition and prodrug include a pharmaceutically acceptable active agent and at least one protein selected from the group consisting of a fimbrial adhesin protein, a membrane protein, and combinations thereof. The inventive compositions and prodrugs of the present invention selectively target the blood-brain barrier and deliver hydrophilic and lipophilic active agents of varying sizes to the central nervous system. | 2010-12-30 |
20100330159 | System for transporting active substances in a biological system - A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles, which is characterized in that the particles are provided with active substance(s) on at least part of their surface, is claimed. Modification of the magnetic particles is not absolutely required in this system. It can be incorporated both into aqueous and oily suspensions and into microemulsions, oil-in-water emulsions, water-in-oil emulsions and also water-in-oil-in-water emulsions. | 2010-12-30 |
20100330160 | Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by | 2010-12-30 |
20100330161 | Oral delivery of tetanus toxoid - Orally active vitamin B | 2010-12-30 |
20100330162 | Spray freeze dry of compositions for pulmonary adminstration - This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles. | 2010-12-30 |
20100330163 | Compositions and Methods for Enhancing Metal Ion Dependent Drug Therapies - Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers. | 2010-12-30 |
20100330164 | METHOD OF INCREASING TEAR PRODUCTION WITH PURINERGIC RECEPTOR AGONISTS - A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form. | 2010-12-30 |
20100330165 | USE OF CHEMOTHERAPEUTIC AGENTS - The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals. | 2010-12-30 |
20100330166 | AGENT FOR ENHANCING ANTI-TUMOR EFFECT COMPRISING OXALIPLATIN LIPOSOME PREPARATION, AND ANTI-TUMOR AGENT COMPRISING THE LIPOSOME PREPARATION - An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects. | 2010-12-30 |
20100330167 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. | 2010-12-30 |
20100330168 | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE AND USES THEREOF - Novel pharmaceutical compositions contain micronized progesterone and at least one oleic safflower oil referred to as safflower oil type II, and medicines comprising said compositions are useful in treating progesterone insufficiency in women. | 2010-12-30 |